Saturday, June 20, 2020 11:00:11 AM
Dear Charles:
I have been a long term investor in Pfizer for many years and I am happy to share with you a report regarding a special drug called Brilacidin developed by Innovative Pharmaceuticals, a small biotech company from Massachusetts has had wonderful success testing a Brilacidin as a therapeutic agent for battling COVID-19.
Two independent RBL labs ( US Regional Biocontainment laboratories ) have verified superior efficacy when using Brilacidin in vitro against COVID-19 virus.
Approximately two weeks ago, one independent lab which have been designated by BARDA to test many novel drugs and the Covid task force set up by President Trump reported that when Brilacidin was exposed to VERO monkey renal cells for one hour then exposed to the Covid 19 virus there was a 75% reduction in infection load. Two independent RBL confirmed the data. https://finance.yahoo.com/news/innovation-pharmaceuticals-brilacidin-reduces-viral-113010146.html
This past week new data came back from the same RBL’s involved with testing for Brilacidin use against Covid 19 in VERO monkey pneumocytes and it showed 95% and 97% reduction in viral load of infection of lung tissues with prior pretreatment with Brilacidin. The p value for the tests was an astonishing (p< .0001) and both labs reported data that was not only promising but outstanding, Covid 19 kills by attaching to and infecting both. https://finance.yahoo.com/news/innovation-pharmaceuticals-brilacidin-inhibits-sars-113010429.html
Brilacidin has already been used safely in three separate human trials, ABSSI, oral mucositis, and for inflammatory bowel disease and has shown a documented safety record and very high bioavailability at several doses given intravenously with very few adverse reactions.
Its mode of action is unique and its classification is a defense-imetic antibiotic with strong anti-inflammatory properties and antiviral properties.
I urge you as a Pfizer investor to look into a possible partnership or directorship of the development of this novel and effective antiviral agent with potent anti-inflammatory properties which will not only help millions of people across the world but also offer great potential value to the Pfizer Corporation.
Pfizer with its world class resources is in a unique position to be a global leader in the successful battle against SARS and Covid 19 and I hope you have already made contact with the company !!
Here is the contact link for reaching out to the CEO Leo Erlich covid19@ipharminc.com
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • Oct 10, 2024 8:09 AM
FEATURED CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM